Timothy Devos

Professor (deeltijds hoofddocent)

KU Leuven

Belgium

Research Interests

Explore related searches

Professors in Belgium

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Timothy Devos is a Professor at KU Leuven in Belgium. His research focuses on hematology, particularly in the areas of leukemia and myeloproliferative disorders. Recent publications include investigations into treatment outcomes for patients with Philadelphia chromosome-positive leukemias and the efficacy of ruxolitinib in resistant polycythemia vera. He is also involved in studies assessing patient-reported outcomes and the role of genetic mutations in erythrocytosis.

Articles (16)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (6)

Alexander Röth

GERMANY

View details

Adrianna Spałek

Medical University of Silesia

POLAND

View details

Ann De Becker

Vrije Universiteit Brussel

BELGIUM

View details

Wim Laleman

BELGIUM

View details

Christopher Patriquin

Assistant Professor

University Health Network

CANADA

View details

Anna Armatys

Medical University of Silesia

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Timothy Devos

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – final 6-year results from a Belgian registry

Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study

Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study

Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria

Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria

CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis

Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case–control study in the International PNH Registry

Germline heterozygous SH2B3‐mutations and (idiopathic) erythrocytosis: Detection of a previously undescribed mutation

Germline heterozygous SH2B3-mutations and (idiopathic) erythrocytosis: Detection of a previously undescribed mutation

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis

Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry

Recanalization of portal axis after cavoportal hemitransposition in a liver transplant recipient with complete splanchnic thrombosis

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases

Collaborators (6)

Alexander Röth

Adrianna Spałek

Ann De Becker

Wim Laleman

Christopher Patriquin

Anna Armatys

Make your next move.